Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of LEA29Y and CTLA4Ig Administered Intravenously to Subjects With Rheumatoid Arthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium
- Local Instiution
-
Diepenbeek, Belgium
- Local Institution
-
Gent, Belgium
- Local Institution
-
Liege 1, Belgium
- Local Institution
-
Mons, Belgium
- Local Institution
-
Pellenberg, Belgium
- Local Institution
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada
- Local Institution
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada
- Local Institution
-
-
Ontario
-
Calgary, Ontario, Canada
- Local Institution
-
Ottawa, Ontario, Canada
- Local Institution
-
Toronto, Ontario, Canada
- Local Institution
-
-
Quebec
-
Montreal, Quebec, Canada
- Local Institution
-
Sherbrook, Quebec, Canada
- Local Institution
-
Ste-Foy, Quebec, Canada
- Local Institution
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada
- Local Institution
-
-
-
-
-
Lille, France
- Local Institution
-
Lyon, France
- Local Institution
-
Montpellier, France
- Local Institution
-
Paris, France
- Local Institution
-
Rennes, France
- Local Institution
-
Strasbourg, France
- Local Institution
-
Toulouse, France
- Local Institution
-
-
-
-
-
Berlin, Germany
- Local Institution
-
Duesseldorf, Germany
- Local Institution
-
Erlangen, Germany
- Local Institution
-
Fankfurt, Germany
- Local Institution
-
Hannover, Germany
- Local Institution
-
Leipzig, Germany
- Local Institution
-
Muenchen, Germany
- Local Institution
-
Muenster, Germany
- Local Institution
-
Ratingen, Germany
- Local Institution
-
-
-
-
-
Cork, Ireland
- Local Institution
-
Dublin, Ireland
- Local Institution
-
-
-
-
-
Amsterdam, Netherlands
- Local Institution
-
Leiden, Netherlands
- Local Institution
-
Nijmegen, Netherlands
- Local Institution
-
-
-
-
-
Bern, Switzerland
- Local Institution
-
-
-
-
-
Birmingham, United Kingdom
- Local Institution
-
Cambridge, United Kingdom
- Local Institution
-
Leeds, United Kingdom
- Local Institution
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
- Local Institution
-
Huntsville, Alabama, United States
- Local Institution
-
-
Arizona
-
Phoenix, Arizona, United States
- Local Institution
-
Tucson, Arizona, United States
- Local Institution
-
-
California
-
Los Angeles, California, United States
- Local Institution
-
San Diego, California, United States
- Local Institution
-
-
Florida
-
Miami, Florida, United States
- Local Institution
-
-
Illinois
-
Chicago, Illinois, United States
- Local Institution
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Local Institution
-
-
Minnesota
-
Duluth, Minnesota, United States
- Local Institution
-
-
New Jersey
-
New Brunswick, New Jersey, United States
- Local Institution
-
-
New York
-
New York, New York, United States
- Local Institution
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
- Local Institution
-
-
Ohio
-
Cincinnati, Ohio, United States
- Local Institution
-
Cleveland, Ohio, United States
- Local Institution
-
-
Oregon
-
Portland, Oregon, United States
- Local Institution
-
-
Tennessee
-
Nashville, Tennessee, United States
- Local Institution
-
-
Texas
-
Dallas, Texas, United States
- Local Institution
-
-
Utah
-
Salt Lake City, Utah, United States
- Local Institution
-
-
Washington
-
Seattle, Washington, United States
- Local Institution
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of RA < 5 years
- Functional class I, II, or II as defined by the American College of Rheumatology (ACR) criteria.
- Must have failed at least 1 Disease Modifying Anit-Rheumatic Drug (DMARD)
- Joint count of 10 or more swollen and 12 or more tender.
- Erythrocyte Sedimentation Rate (ESR) > - 28mm/rr or norning stiffness > - 45 minutes.
Exclusion Criteria:
- Women and men who are not willing to use an accepted form of contraception.
- Active vasculitis
- Treatment with another investigational drug within 30 days
- History of asthma, angioedema, or anaphylaxix
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Assess the relative safety and preliminary efficacy (clinical activity) of BMS-188667 and BMS-224818 in subjects with rheumatoid arthritis (RA)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Assess the immunogenicity of BMS-188667 and BMS-224818 in subjects with RA, and in a site specific substudy to the protocol, the pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-188667 and BMS-224818 in subjects with RA
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Immune Checkpoint Inhibitors
- Abatacept
Other Study ID Numbers
Other Study ID Numbers
- IM103-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.